Investigational Vaccine Generates Immune Response to KRAS Mutations in Pancreatic Cancer Study

About 90% of pancreatic cancers are driven by KRAS mutations. A new pancreatic cancer vaccine taught the immune system to attack these mutations in 89 of 90 patients, and those with the strongest immune response stayed cancer-free for longer. A larger phase 3 trial is now planned.

Investigational vaccine generates immune response to KRAS mutations in pancreatic cancer study

An investigational vaccine helped the immune system recognize and respond to mutations that drive most pancreatic cancers, according to results from a randomized phase 2 clinical trial led by Mayo Clinic researchers. The findings, published in Nature Medicine, will help researchers design a larger phase 3 clinical trial.

KRAS-targeting vaccine prompts immune responses in pancreatic cancer patients

An investigational vaccine helped the immune system recognize and respond to mutations that drive most pancreatic cancers, according to results from a randomized phase 2 clinical trial led by Mayo Clinic researchers.